MA43106A - Traitement de l'oligo-ovulation associée à la stéatose hepatique - Google Patents

Traitement de l'oligo-ovulation associée à la stéatose hepatique

Info

Publication number: MA43106A
Authority: MA; Morocco
Prior art keywords: oligo; treatment; hepatic steatosis; ovulation; ovulation associated
Prior art date: 2015-10-27

Application number

MA043106A

Other languages

English (en)

Other versions

MA43106B1 (fr

Inventor

Zegher Francis De

Lourdes Ibáñez

Original Assignee

Sant Joan De Deu Hospital

Univ Leuven Kath

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-27

Filing date

2016-10-27

Publication date

2021-05-05

2016-10-27 Application filed by Sant Joan De Deu Hospital, Univ Leuven Kath filed Critical Sant Joan De Deu Hospital

2021-05-05 Publication of MA43106A publication Critical patent/MA43106A/fr

2021-09-30 Publication of MA43106B1 publication Critical patent/MA43106B1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pregnancy & Childbirth (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA43106A 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hepatique MA43106B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1518979.8A GB201518979D0 (en)	2015-10-27	2015-10-27	Treatment of hepatic steatosis related oligo-ovulation
PCT/EP2016/075953 WO2017072243A1 (fr)	2015-10-27	2016-10-27	Traitement de l'oligo-ovulation associée à la stéatose hépatique

Publications (2)

Publication Number	Publication Date
MA43106A true MA43106A (fr)	2021-05-05
MA43106B1 MA43106B1 (fr)	2021-09-30

Family

ID=55130283

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA054412A MA54412A (fr)	2015-10-27	2016-10-27	Traitement d'excès de graisse hépatique et/ou viscérale
MA43106A MA43106B1 (fr)	2015-10-27	2016-10-27	Traitement de l'oligo-ovulation associée à la stéatose hepatique

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA054412A MA54412A (fr)	2015-10-27	2016-10-27	Traitement d'excès de graisse hépatique et/ou viscérale

Country Status (24)

Country	Link
US (2)	US20190060328A1 (fr)
EP (2)	EP3892281A3 (fr)
JP (2)	JP6999903B2 (fr)
KR (1)	KR102608158B1 (fr)
CN (2)	CN108778285A (fr)
AR (1)	AR106505A1 (fr)
AU (1)	AU2016344737C1 (fr)
BR (1)	BR112018008496A2 (fr)
CA (1)	CA3003076C (fr)
DK (1)	DK3368044T3 (fr)
ES (1)	ES2883282T3 (fr)
GB (1)	GB201518979D0 (fr)
HU (1)	HUE055778T2 (fr)
IL (1)	IL258876B (fr)
LT (1)	LT3368044T (fr)
MA (2)	MA54412A (fr)
MX (2)	MX384040B (fr)
PL (1)	PL3368044T3 (fr)
RS (1)	RS62764B1 (fr)
RU (1)	RU2745606C2 (fr)
SI (1)	SI3368044T1 (fr)
TW (1)	TWI791420B (fr)
UY (1)	UY36967A (fr)
WO (1)	WO2017072243A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY207644A (en)	2017-12-19	2025-03-07	Akouos Inc	Aav-mediated delivery of therapeutic antibodies to the inner ear
KR20210045404A (ko) *	2018-08-02	2021-04-26	오스피탈 산트 호안 데 데우	다낭성 난소 증후군 치료에 유용한 활성 약학적 성분들의 삼중 조합의 즉시 방출 제제
EP3842803A1 (fr) *	2019-12-23	2021-06-30	Katholieke Universiteit Leuven	Cxcl14 dans le syndrome des ovaires polykystiques
CN116801911A (zh)	2020-05-13	2023-09-22	阿库斯股份有限公司	用于治疗slc26a4相关听力损失的组合物和方法
WO2022119839A1 (fr)	2020-12-01	2022-06-09	Akouos, Inc.	Constructions d'anticorps anti-vegf et procédés associés pour le traitement de symptômes associés au neurinome de l'acoustique
US20240139344A1 (en)	2020-12-29	2024-05-02	Akouos, Inc.	Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
AU2023215253A1 (en)	2022-02-02	2024-09-19	Akouos, Inc.	Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5478852C1 (en) *	1993-09-15	2001-03-13	Sankyo Co	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US6046222A (en) *	1993-09-15	2000-04-04	Warner-Lambert Company	Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
CA2406871A1 (fr) *	2000-02-23	2001-08-30	Orentreich Foundation For The Advancement Of Science, Inc.	Methodes et compositions de traitement de l'alopecie et d'autres troubles de l'appareil pilosebace
GB0106565D0 (en) *	2001-03-16	2001-05-09	Leuven K U Res & Dev	Growth hormone treatment
GB0108863D0 (en) *	2001-04-10	2001-05-30	Leuven K U Res & Dev	Combinational therapy
US7105489B2 (en) *	2002-01-22	2006-09-12	Amylin Pharmaceuticals, Inc.	Methods and compositions for treating polycystic ovary syndrome
JP2006520747A (ja) *	2002-12-11	2006-09-14	アミリン・ファーマシューティカルズ，インコーポレイテッド	多嚢胞性卵巣症候群を治療するための方法および組成物
GB0702537D0 (en)	2007-02-12	2007-03-21	Leuven K U Res & Dev	Treatment for excessive adiposity
US10474539B1 (en) *	2015-12-18	2019-11-12	EMC IP Holding Company LLC	Browsing federated backups
KR20210045404A (ko) *	2018-08-02	2021-04-26	오스피탈 산트 호안 데 데우	다낭성 난소 증후군 치료에 유용한 활성 약학적 성분들의 삼중 조합의 즉시 방출 제제

2015
- 2015-10-27 GB GBGB1518979.8A patent/GB201518979D0/en not_active Ceased
2016
- 2016-10-27 JP JP2018521981A patent/JP6999903B2/ja active Active
- 2016-10-27 EP EP21165556.8A patent/EP3892281A3/fr not_active Withdrawn
- 2016-10-27 PL PL16788501T patent/PL3368044T3/pl unknown
- 2016-10-27 US US15/771,317 patent/US20190060328A1/en not_active Abandoned
- 2016-10-27 AR ARP160103272A patent/AR106505A1/es unknown
- 2016-10-27 SI SI201631327T patent/SI3368044T1/sl unknown
- 2016-10-27 CN CN201680076653.5A patent/CN108778285A/zh active Pending
- 2016-10-27 KR KR1020187014890A patent/KR102608158B1/ko active Active
- 2016-10-27 DK DK16788501.1T patent/DK3368044T3/da active
- 2016-10-27 ES ES16788501T patent/ES2883282T3/es active Active
- 2016-10-27 RU RU2018119146A patent/RU2745606C2/ru active
- 2016-10-27 HU HUE16788501A patent/HUE055778T2/hu unknown
- 2016-10-27 LT LTEPPCT/EP2016/075953T patent/LT3368044T/lt unknown
- 2016-10-27 RS RS20211116A patent/RS62764B1/sr unknown
- 2016-10-27 CN CN202311150878.9A patent/CN117379440A/zh active Pending
- 2016-10-27 TW TW105134878A patent/TWI791420B/zh active
- 2016-10-27 MX MX2018005252A patent/MX384040B/es unknown
- 2016-10-27 AU AU2016344737A patent/AU2016344737C1/en active Active
- 2016-10-27 EP EP16788501.1A patent/EP3368044B1/fr active Active
- 2016-10-27 WO PCT/EP2016/075953 patent/WO2017072243A1/fr not_active Ceased
- 2016-10-27 UY UY0001036967A patent/UY36967A/es unknown
- 2016-10-27 BR BR112018008496A patent/BR112018008496A2/pt not_active Application Discontinuation
- 2016-10-27 MA MA054412A patent/MA54412A/fr unknown
- 2016-10-27 MA MA43106A patent/MA43106B1/fr unknown
- 2016-10-27 CA CA3003076A patent/CA3003076C/fr active Active
2018
- 2018-04-23 IL IL258876A patent/IL258876B/en unknown
- 2018-04-26 MX MX2021007976A patent/MX2021007976A/es unknown
2021
- 2021-10-21 JP JP2021172610A patent/JP2022009374A/ja active Pending
2023
- 2023-06-28 US US18/343,553 patent/US20240000804A1/en active Pending

Also Published As

Publication number	Publication date
CA3003076A1 (fr)	2017-05-04
AU2016344737B2 (en)	2021-07-08
GB201518979D0 (en)	2015-12-09
KR20180098234A (ko)	2018-09-03
WO2017072243A8 (fr)	2018-03-22
IL258876A (en)	2018-06-28
EP3368044A1 (fr)	2018-09-05
CN108778285A (zh)	2018-11-09
EP3892281A2 (fr)	2021-10-13
WO2017072243A9 (fr)	2018-07-26
PL3368044T3 (pl)	2021-12-20
SI3368044T1 (sl)	2022-05-31
WO2017072243A1 (fr)	2017-05-04
LT3368044T (lt)	2021-10-25
JP2019501113A (ja)	2019-01-17
EP3368044B1 (fr)	2021-06-09
US20240000804A1 (en)	2024-01-04
RU2018119146A3 (fr)	2020-02-25
IL258876B (en)	2022-03-01
RS62764B1 (sr)	2022-01-31
EP3892281A3 (fr)	2021-11-10
MX384040B (es)	2025-03-14
RU2745606C2 (ru)	2021-03-29
CA3003076C (fr)	2023-12-05
UY36967A (es)	2017-05-31
CN117379440A (zh)	2024-01-12
MX2018005252A (es)	2018-09-18
HUE055778T2 (hu)	2021-12-28
RU2018119146A (ru)	2019-11-28
MX2021007976A (es)	2021-08-16
AR106505A1 (es)	2018-01-24
JP2022009374A (ja)	2022-01-14
BR112018008496A2 (pt)	2018-10-23
JP6999903B2 (ja)	2022-02-04
MA43106B1 (fr)	2021-09-30
US20190060328A1 (en)	2019-02-28
AU2016344737C1 (en)	2021-10-07
AU2016344737A9 (en)	2018-08-09
AU2016344737A1 (en)	2018-05-17
MA54412A (fr)	2021-11-10
ES2883282T3 (es)	2021-12-07
TWI791420B (zh)	2023-02-11
DK3368044T3 (da)	2021-09-13
KR102608158B1 (ko)	2023-11-29
TW201720432A (zh)	2017-06-16

Publication	Publication Date	Title
MA45192A (fr)	2019-04-10	Traitement d'association
EP3370721A4 (fr)	2019-05-22	Traitement de l'ostéoarthrite
EP3464313A4 (fr)	2020-02-26	Nucléotides modifiés 5 '-cyclo-phosphonate
MA46180A (fr)	2021-03-24	Analogues de l'amyline
PT3368534T (pt)	2021-03-09	Ditosilato de valbenazina e polimorfos do mesmo
EP3360554A4 (fr)	2019-05-22	Agent anti-virus de l'hépatite b
EP3325963A4 (fr)	2019-08-14	Amélioration de l'estimation de globules
MA40867A (fr)	2017-09-06	Méthodes pour le traitement d'infections virales à filoviridae
EP3261641A4 (fr)	2019-05-22	Traitement de la pancréatite
FR3036037B1 (fr)	2017-05-26	Harnais d'encordement perfectionne
EP3340971A4 (fr)	2019-05-01	Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine
EP3443094A4 (fr)	2019-12-11	Procédés de réduction de l'expression de c9orf72
MA46788A (fr)	2019-09-18	Traitement de la fibrose
MA43106A (fr)	2021-05-05	Traitement de l'oligo-ovulation associée à la stéatose hepatique
EP3250367A4 (fr)	2019-01-09	Étalonnage d'agent
EP3375108A4 (fr)	2019-10-23	Traitement dewlan
EP3347334A4 (fr)	2019-05-01	Déshydrohalogénation d'hydrochlorofluorocarbones
LT3307267T (lt)	2019-07-25	Išsėtinės sklerozės gydymas
EP3347032A4 (fr)	2019-06-19	Traitement de l'ascite
EP3454793A4 (fr)	2019-10-23	Bobines de traitement d'anévrisme
DK3706699T3 (da)	2021-05-10	Badekonstruktion
EP3328384A4 (fr)	2019-03-06	Traitement de la fibrose
EP3309165A4 (fr)	2019-03-06	Agent de traitement de surface
MA41782A (fr)	2018-01-23	Traitement de patients atteints de diabète de type 2
EP3294313A4 (fr)	2019-04-17	Méthodes associées à la prévention et et au traitement d'une pharmacorésistance